Last edition
News about "Halozyme Therapeutics"
European Commission Approves DARZALEX Faspro for Adults with Smouldering Multiple Myeloma
Halozyme Therapeutics has announced European Commission approval for DARZALEX Faspro, co-formulated with ENHANZE, as a monotherapy for high-risk smouldering multiple myeloma in adults, marking a shift from passive monitoring to early intervention.
Halozyme Therapeutics | 24/07/2025 | By Mrinmoy Dey | 119
Halozyme Announces Takeda Gets Approval for HYQVIA with ENHANZE in Japan
HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10 percent and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE drug delivery technology.
Halozyme Therapeutics | 31/12/2024 | By Aishwarya | 278
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza with ENHANZE
Tecentriq Hybreza can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) infusion of Tecentriq (atezolizumab).
Halozyme Therapeutics | 13/09/2024 | By Aishwarya | 417
argenx Secures FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE
Halozyme Therapeutics has announced that argenx has received US Food and Drug Administration (FDA) approval for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy.
Halozyme Therapeutics | 24/06/2024 | By Aishwarya | 498
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy